Mark Stoopler

Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

Catherine A. Shu, Justin F. Gainor, Mark M. Awad et al. · The Lancet Oncology · 2020 · 640 citations

Medicine, Oncology, Pharmacology +14

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable <i>MET</i> Gene Mutations

Xuewen Liu, Yuxia Jia, Mark Stoopler et al. · Journal of Clinical Oncology · 2015 · 341 citations

Medicine, Molecular Genetics, Oncology +17

PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens

Jonas J. Heymann, William A. Bulman, David Swinarski et al. · Cancer Cytopathology · 2017 · 206 citations · Full text

Medicine, Oncology, Pathology +17

Lysyl oxidase: A lung adenocarcinoma biomarker of invasion and survival

May‐Lin Wilgus, Alain Borczuk, Mark Stoopler et al. · Cancer · 2010 · 77 citations

Medicine, Cancer Biology, Oncology +17

Effects of β-Adrenergic Antagonists on Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer

Kunal Chaudhary, S.X. Yan, Samuel P. Heilbroner et al. · Journal of Clinical Medicine · 2019 · 60 citations · Full text

Medicine, Oncology, Pharmacology +17